MedTech News
Saluda Medical Receives FDA Approval for First Automated Programming Platform in SCS
MINNEAPOLIS, Jan. 23, 2025 /PRNewswire/ — Saluda Medical, Inc., a pioneer in the development and commercialization of a novel neuromodulation platform designed to transform the lives of patients with chronic neurological conditions, today announced United States (U.S.) Food & Drug Administration (FDA) approval for its biomarker-based, automated patient programming platform in spinal cord stimulation (SCS), representing a significant advancement for SCS therapy.
Blackrock Neurotech arrays used in BCI that enables finger-based control using only thought
Blackrock Neurotech announced that researchers used its microelectrode arrays to develop a high-performance brain-computer interface (BCI).
L&C Bio Secures World’s First NMPA Approval for ‘MegaDerm Plus’ in China
SEONGNAM-SI, South Korea, Jan. 22, 2025 /PRNewswire/ — L&C Bio (CEO Hwan-Chul Lee) has achieved a significant milestone in its global market strategy by becoming the first company worldwide to secure approval from China’s National Medical Products Administration (NMPA) for its acellular dermal matrix, “MegaDerm Plus.”
Innovative bioprinting method creates heart tissues with dynamic shape changes
Researchers at University of Galway have developed a way of bioprinting tissues that change shape as a result of cell-generated forces, in the same way that it happens in biological tissues during organ development.
FDA clears Nalu peripheral nerve stim tech for whole-body MRI
Nalu Medical announced today that the FDA cleared expanded labeling of its peripheral nerve system to include whole-body MRI use.
Trump is back: Here’s what his initial actions mean for medtech
President Donald Trump has returned to office and swiftly enacted a series of executive orders that could impact the medtech industry.
Datar Cancer Genetics Introduces Revolutionary Tumor-Agnostic + Informed Blood Test for Residual Disease Monitoring
LONDON and MUNICH and NEW DELHI, Jan. 21, 2025 /PRNewswire/ — Datar Cancer Genetics (DCG) today announced the launch of Target-MRD, an advanced molecular residual disease (MRD) monitoring blood test for solid organ cancers. Target-MRD is a blood test based on tumor-agnostic next-generation sequencing (NGS) and customized, tumor-informed droplet digital PCR (dd-PCR) assay.
Inflammatix Receives FDA Clearance for First-in-Class TriVerity™ Test
SUNNYVALE, Calif., Jan. 21, 2025 /PRNewswire/ — Inflammatix, a pioneering host response diagnostics company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing authorization for the TriVerity™ Test System (TriVerity), a first-in-class molecular test for patients with suspected acute infection or sepsis. Using precise measurements of a patient’s immune response, TriVerity combines highly accurate bacterial-viral infection scoring with an all-cause illness severity risk evaluation, giving clinicians a rapid and holistic snapshot of a patient’s status.